Streetbeat News

KTTAW

Pasithea Therapeutics Corp.

Industry

Biotechnology

Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders. The company also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine. Pasithea Therapeutics Corp. was incorporated in 2020 and is based in Miami Beach, Florida.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Pasithea Therapeutics Corp. (NASDAQ:KTTA) announced a $5 million private placement to fund next-gen cancer treatments. The offering includes 1.2 million shares at $4.10 each, with accompanying warrants. Proceeds will support working capital and corporate purposes.

Portfolio Pulse from Benzinga Newsdesk

September 27, 2024 | 7:03 am

Trading for KTTAW was halted and then resumed at 9:00:00 AM ET following an update on quotation resumption, news, and resumption times.

Portfolio Pulse from Benzinga Newsdesk

January 02, 2024 | 2:00 pm

Trading for KTTAW has been halted at 7:50:00 p.m. ET due to pending news. No further details are provided about the nature of the news or when trading will resume.

Portfolio Pulse from Benzinga Newsdesk

December 30, 2023 | 12:50 am

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.